The Semaglutide peptide has emerged as a compelling subject in biochemical and physiological research due to its potential ...

A new study led by Ananda Basu, M.D., used novel non-radioactive, stable glucagon tracers for the first time to characterize glucagon metabolism in humans with and without Type 1 diabetes ...

A study explored glucagon metabolism in humans with and without Type 1 diabetes using stable glucagon tracers. Findings reveal significant differences in splanchnic and leg glucagon metabolism.

Ananda Basu, M.D. A new study led by Ananda Basu, M.D., used novel non-radioactive, stable glucagon tracers for the first time to characterize glucagon metabolism in humans with and without Type 1 ...

Association of glucagon-like peptide 1 receptor agonists with cancer risk in obesity adults with and without diabetes: A target trial emulation study.. If you have the appropriate software installed, ...

Glucagon like peptide-1 (GLP-1), product of the glucagon gene is one of the prime components which stimulates the β cell proliferation and inhibits β cell death. DiPeptidyl Peptidase IV (DPP IV) acts ...

According to Monday’s news release, the candidate, OPK-88006, is set to be the first oral GLP-1/glucagon agonist to start human studies. Under the terms of the agreement, OPKO and Entera will split ...

Opko and Entera have formalized their partnership as the biotechs prepare to take the first oral dual agonist GLP-1/glucagon peptide into the clinic.

Glucagon prescriptions for severe hypoglycemia rose in Medicaid beneficiaries with the introduction of newer products but likely met only a fraction of the high-risk population’s needs.

As a counter to insulin, glucagon plays a vital role in diabetes, maintaining blood sugar levels and offering therapeutic potential for hypoglycemia.

Tests in mice suggest glucagon micelle could be used as a responsive system to prevent the onset of insulin-induced deep hypoglycemia.